<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054687</url>
  </required_header>
  <id_info>
    <org_study_id>19-001</org_study_id>
    <nct_id>NCT04054687</nct_id>
  </id_info>
  <brief_title>Intranasal TXA for Anterior Epistaxis in the Emergency Department</brief_title>
  <official_title>Intranasal TXA for Anterior Epistaxis in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Health Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Health Ohio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of and patient satisfaction with the
      use of intranasal tranexamic acid (TXA) for anterior nosebleeds in the emergency department
      (ED).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pledget soaked in either saline or TXA will be applied to the bleeding nare of the patient
      presenting with anterior epistaxis. After fifteen minutes, the pledget will be removed and
      patient reassessed.

      Informed consent will be obtained prior to patient enrollment.

      Enrolled patients will be placed in one of two groups: either the group receiving a cotton
      pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to
      gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget.
      After fifteen minutes the pledget will be removed. If patient continues to bleed within a
      reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will
      pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked
      pledget and the procedure will continue like Group 1.

      Patient satisfaction will be assessed in both groups during ED stay and one week after ED
      stay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding cessation</measure>
    <time_frame>15 minutes</time_frame>
    <description>After 15 minutes of patient receiving either pledget filled TXA or placebo, bleeding will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction: 10 point scale</measure>
    <time_frame>Before ED discharge (up to 24 hours) and 1 week after ED discharge</time_frame>
    <description>Patient satisfaction will be assessed at the end of the emergency department encounter, and then again via telephone call one week after discharge using a 10 point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding cessation</measure>
    <time_frame>1 week</time_frame>
    <description>Patients will be contacted 1 week after ED discharge to determine whether there was a recurrence of his/her epistaxis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Epistaxis</condition>
  <arm_group>
    <arm_group_label>TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research participants in the experimental group will receive one dose of 100mg/mL TXA soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Research participants in the placebo group will receive one dose of normal saline (0.9%) soaked in a cotton pledget in the bleeding nare for a total of 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.</description>
    <arm_group_label>TXA</arm_group_label>
    <other_name>TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This group will receive pledget soaked in saline. Protocol will continue as with TXA group.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        â€¢ Patients 18 years and older with anterior epistaxis

        Exclusion criteria:

          -  Patients with inability to give consent

          -  Patients without a working telephone number

          -  Patients lacking the mental capacity to make their own decisions

          -  Patients with posterior epistaxis

          -  Epistaxis following major trauma

          -  Patients with known bleeding disorder like hemophilia and thrombocytopenia

          -  Prisoners

          -  Patients hemodynamically unstable

          -  Pregnant patients

          -  Patients with a known allergy to TXA

          -  Patients with a visibly bleeding vessel

          -  Those recently post-op nasal/sinus surgery (within ten days) will also be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Barreiro</last_name>
    <role>Study Chair</role>
    <affiliation>Mercy Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noga</last_name>
    <phone>724.944.7500</phone>
    <email>JNoga@Mercy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Elizabeth Boardman Hospital</name>
      <address>
        <city>Boardman</city>
        <state>Ohio</state>
        <zip>44512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Noga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Elizabeth Youngstown</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Noga</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epistaxis</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT04054687/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

